The three-year trial results revealed that a once-a-week tirzepatide injection for adults who are prediabetic, obese, or overweight reduced their risk of progressing to type 2 diabetes by 94%.

The study tested a new weight loss program called the Individualized Diet Improvement Program (iDip) which involves increasing protein and fiber intake while consuming 1,500 calories or less daily for one year.